LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Sangamo Therapeutics Inc

Aperta

SettoreSettore sanitario

0.51 -5.56

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.51

Massimo

0.54

Metriche Chiave

By Trading Economics

Entrata

11M

-20M

Vendite

12M

18M

Margine di Profitto

-109.177

Dipendenti

183

EBITDA

9.6M

-18M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+763.64% upside

Dividendi

By Dow Jones

Utili prossimi

11 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

26M

157M

Apertura precedente

6.07

Chiusura precedente

0.51

Notizie sul Sentiment di mercato

By Acuity

50%

50%

173 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Sangamo Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 dic 2024, 11:35 UTC

I principali Market Mover

Sangamo Shares Rally Premarket on License Deal With Astellas

Confronto tra pari

Modifica del prezzo

Sangamo Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

763.64% in crescita

Previsioni per 12 mesi

Media 4.75 USD  763.64%

Alto 10 USD

Basso 2 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

3

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.5207 / 0.7223Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

173 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
help-icon Live chat